Finzati - Logo
ALNY logo

Alnylam Pharmaceuticals, Inc.

ALNY • Biotechnology
$266.11
▲ +1.61 (+0.61%)
Current price
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$36.79B
Growth
—
Cash Flow
2/5
Trend
Volatile
Evidence
Positive revenue growth · 41.2%Positive free cash flow · 3.55Healthy liquidity · 2.76Expensive earnings multiple · 166.04
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$266.11
Change0.61%
Shares Out138.25M
Market Cap$36.79B
Enterprise Value$34.75B
52W Range197.81 - 495.55
Beta0.27
P/E45.53
P/S7.66
P/B27.17
P/FCF46.34
EV/Sales7.23

Investment DNA

How strong this company looks for long-term investors

64
out of 100
Business Quality
Margins, moat, returns
67/100
Financial Strength
Debt, cash, stability
62/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Positive revenue growth · 41.2%Positive free cash flow · 3.55Healthy liquidity · 2.76Expensive earnings multiple · 166.04

Analyst view

Analyst sentiment and price target

ALNY
Analyst sentiment
Based on 52 analyst votes · 2026-09-05
87/100
Bullish
Bullish
39
Hold
12
Bearish
1
Price Target
2026-07-31
Low
$400.00
Mean
$438.50
Median
$436.50
High
$485.00

Company Overview

IPO: 6/1/2004
Industry: Biotechnology
P/B i: 27.17
Debt / Equity i: 1.62
Operating Margin: 13.51%
Net Margin: 8.45%
ROE i: -
ROIC: -

Financial Health

Score12 / 20
Debt / Equity: 1.62
Current Ratio: 2.76
Quick Ratio: 2.71
Status: Good

Insider Transactions

Recent executive and insider activity

Cravatt Benjamin
Transaction: 06/01/2026
OTHER
Change
0
Price
Not reported
Filing
06/03/2026
Type
OTHER
Cravatt Benjamin
Transaction: 06/01/2026
BUY
Change
+4,393
Price
$295.63
Filing
06/03/2026
Type
BUY
PYOTT DAVID E I
Transaction: 06/01/2026
SELL
Change
-3,830
Price
$70.20
Filing
06/03/2026
Type
SELL